文章：

开启乳腺癌治疗新途径：激酶抑制剂与免疫疗法的协同作用

Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

原文发布日期：21 November 2023

DOI: 10.3390/cancers15235499

类型: Article

开放获取: 是

英文摘要：

Cancer is one of the world’s most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments.

摘要翻译： 

癌症是当今世界最严峻的健康问题之一。目前，乳腺癌已超越肺癌成为全球女性最常见的恶性肿瘤。2020年，全球女性新确诊乳腺癌病例约达2,261,419例。因此，有必要深入理解相关病理机制以提升疾病治疗效果。近年来，癌症治疗研究主要围绕两种治疗模式展开：其一是蛋白激酶抑制剂的应用，该疗法为新型治疗策略的发展提供了关键支持；另一重要途径是免疫疗法的运用，该疗法被公认为癌症治疗领域的重要突破。蛋白激酶的功能异常可能影响包括免疫疗法在内的其他治疗手段的疗效。本文综述将系统分析蛋白激酶异常在乳腺癌中的作用机制，及其对免疫治疗应答效果可能产生的影响。

原文链接：

Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy